Faron Pharmaceuticals Ltd.
("Faron" or "the Company")
Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
Press release, August 02, 2023
Management to present on Thursday, August 10 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston,Massachusetts
Presentation will highlight recent updated positive Phase I/II BEXMAB data of bexmarilimab in relapsed/refractory AML and MDS
TURKU, Finland / BOSTON, Massachusetts- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's Chief Executive Officer, Dr. Markku Jalkanen, and Chief Medical Officer, Dr. Marie-Louise Fjllskog, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts, in Room Abigail Adams C.
The Company will discuss the most recent positive clinical data from the Company's ongoing Phase I/II BEXMAB study, investigating bexmarilimab, Faron's wholly owned immunotherapy asset, in combination with standard of care (SoC) in the aggressive hematological malignancies of r/r acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The updated BEXMAB data support advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA). The Company's filing of its first Biologics License Application (BLA) to the FDA is planned for H1 2025.
A live webcast of the fireside chat can be found here and in the Investor Relations section of Faron's website at https://www.faron.com/investors/results-presentations. Following the completion of the event, a webcast replay of the fireside chat will be available on the website for 90 days.
For more information please contact:
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
+1 (617) 430-7576
Media Contact
Faron Pharmaceuticals
Jennifer C. Smith-Parker
Head of Communications
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Jrvel
Phone: +358 (0)50 553 8990
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.
About BEXMAB
The BEXMAB study is a first-in-human, open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment and to identify the recommended Phase II dose. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tacklingcancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDNRAPBMATMTAMBLJ